Disposition of 1,2,3,4,-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats

Brain Research

Volumn 996, Issue 2, 2004, Pages 168-179

  Lorenc Koci, Elzbieta ^a   Wójcikowski, Jacek ^b   Kot, Marta ^b   Haduch, Anna ^b   Boksa, Jan ^a   Daniel, Władysława Anna ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

1,2,3,4 Tetrahydroisoquinoline content in striatum and substantia nigra; 1,2,3,4 Tetrahydroisoquinoline transport and disposition; Inhibition of CYP2D; Quinine

Indexed keywords

CARRIER PROTEIN; CYTOCHROME P450 2D; GLYCOPROTEIN P; OCTAPEPTIDE; QUININE; QUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG TRANSPORT; ENZYME INHIBITION; HYDROXYLATION; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0346102800     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.10.023     Document Type: Article

References (69)

1. Antkiewicz-Michaluk L., Romañska I., Papla I., Michaluk J., Bakalarz M., Vetulani J., Krygowska-Wajs A., Szczudlik A. Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and sansolinol in dopaminergic structures of rat brain. Neuroscience. 96:2000;59-64.
2. Arvin M., Fedorkova L., Disshon K.A., Dluzen D.E., Leipheimer R.E. Estrogen modulates responses of striatal dopamine neurons to MPP+: evaluations using in vitro and in vivo techniques. Brain Res. 872:2000;160-171.
3. Barbeau A., Roy M., Paris S., Cloutier T., Plasse L., Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet. 2:1985;1213-1215.
4. Barham H.M., Lennard M.S., Tucker G.T. An evaluation of cytochrome P450 isoform activities in the female Dark Agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem. Pharmacol. 47:1994;1295-1307.
5. Bon M.A.M., Jansen Steur E.N.H., de Vos R.A.I., Vermes I. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism. Neurosci. Lett. 266:1999;149-151.
6. Callier S., Morissette M., Grandbois M., Pélaprat D., Di Paolo T. Neuroprotective properties of 17β-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse. 41:2001;131-138.
7. Callier S., Le Saux M., Lhiaubet A.-M., Di Paolo T., Rosténe W., Pélaprat D. Evaluation of the protective effect of oestriadol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurons in primary culture. J. Neurochem. 80:2002;307-316.
8. Checkoway H., Farin F.M., Costa-Mallen P., Kirchner S.C., Costa L.G. Genetic polymorphism in Parkinson's disease. Neurotoxicology. 19:1998;635-644.
9. Coleman T., Ellis S.W., Martin I.J., Lennard M.S., Tucker G.T. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 277:1996;685-690.
10. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by enothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A. 86:1989;695-698.
11. Dluzen D.E., McDermott J.L., Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J. Neurochem. 66:1996;658-666.
12. Fang J., Gorrod J.W. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell. Mol. Neurobiol. 19:1999;491-509.
13. Furuno T., Landi M.T., Ceroni M., Caporaso N., Bernucci I., Nappi G., Martignoni E., Schaeffeler E., Eichelbaum M., Schwab M., Zanger U.M. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. 12:2002;529-534.
14. Gilham D.E., Cairns W., Paine M.J.I., Modi S., Poulsom R., Roberts G.C.K., Wolf C.R. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica. 27:1997;111-125.
15. Glare P.A., Walsh T.D., Pippenger C.E. A simple, rapid method for the simultaneous determination of morphine and its principal metabolites in plasma using high-performance liquid chromatography and fluorometric detection. Ther. Drug Monit. 13:1991;226-232.
16. Gorboulev V., Ulzheimer J.C., Akhoundova A., Ulzheimer-Teuber I., Karbach U., Quester S., Baumann C., Lang F., Busch A.E., Koepsell H. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16:1997;871-881.
17. Grandbois M., Morissette M., Callier S., Di Paolo T. Ovarian steroids and reloxifene prevent MPTP-induced dopamine depletion in mice. NeuroReport. 11:2000;343-346.
18. 1 cells. J. Biol. Chem. 272:1997;10408-10413.
19. Hardy J., Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science. 282:1998;1075-1079.
20. Hiroi T., Imaoka S., Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249:1998;838-843.
21. Hiroi T., Chow T., Imaoka S., Funae Y. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab. Dispos. 30:2002;970-976.
22. Jetté L., Murphy G.F., Leclerc J.-M., Béliveau R. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem. Parmacol. 50:1995;1701-1709.
23. Jiménez-Jiménez F.J., Tabernero C., Mena M.A., Garcia de Yébenes J., Garcia de Yébenes M.J., Casarejos M.J., Pardo B., Garcia-Agundez J.A., Benitez J., Martinez A., Garcia-Asenjo J.A.L. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J. Neurochem. 57:1991;81-87.
24. Kawashima H., Strobel H.W. cDNA cloning of a novel rat brain cytochrome P450 belonging to the CYP2D subfamily. Biochem. Biophys. Res. Commun. 209:1995;535-540.
25. Kempermann G., Knoth R., Gebucke-Haerter P.J., Stolz B.J., Volk B. Cytochrome P450 in rat astrocytes in vivo and in vitro: intracellular localization and induction by phenytoin. J. Neurosci. Res. 39:1994;576-588.
26. Kikuchi K., Nagatsu Y., Makino Y., Mashino T., Ohta S., Hirobe M. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4- tetrahydroisoquinoline. Drug Metab. Dispos. 19:1990;257-262.
27. Kimura S., Umeno M., Skoda R.C., Meyer U.A., Gonzalez F.J. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45:1989;889-904.
28. Kobayashi S., Murray S., Watson D., Sesardic D., Davies D.S., Boobis A.R. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem. Pharmacol. 38:1989;2795-2799.
29. Kohno M., Ohta S., Hirobe M. Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem. Biophys. Res. Commun. 140:1986;448-454.
30. Kroemer H.K., Eichelbaum M. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56:1995;2285-2298.
31. Kupfenberg H., Burkhalter A., Way E.L. A sensitive fluorometric assay for morphine in plasma and brain. J. Pharmacol. Exp. Ther. 145:1964;247-251.
32. Lang A.E., Lozano A.M. Parkinson's disease, first of two parts. N. Engl. J. Med. 339:1998;1044-1053.
33. Lankas G.R., Cartwright M.E., Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 143:1997;357-365.
34. Lee G., Dallas S., Hong M., Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:2001;569-596.
35. Lorenc-Koci E., Śmialowska M., Antkiewicz-Michaluk L., Golembiowska K., Bajkowska M., Wolfarth S. Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats. Neuroscience. 95:2000;1049-1059.
36. Makino Y., Ohta S., Tachikawa O., Hirobe M. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: compounds related to Parkinson's disease. Life Sci. 43:1988;373-378.
37. Martinez C., Agundez J.A.G., Gervasini G., Martin R., Benitez J. Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics. 7:1997;85-93.
38. Matsunaga E., Umeno M., Gonzalez F.J. The rat P450 IID subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme-binding region of the cytochrome P450 active site. J. Mol. Evol. 30:1990;155-169.
39. McNaught K.St.P., Carrupt P.-A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem. Pharmacol. 56:1998;921-933.
40. Miksys S., Rao Y., Sellers E.M., Kwan M., Mendis D., Tyndale R.F. Regional and cellular distribution subfamily members in rat brain. Xenobiotica. 30:2000;547-564.
41. Miller D.B., Ali S.F., O'Callghan J.P., Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. N.Y. Acad. Sci. 844:1998;153-165.
42. Murakami H., Sawada N., Koyabu N., Ohtani H., Sawada Y. Characteristics of choline transport across the blood brain in mice: correlation with in vitro data. Pharm. Res. 17:2000;1526-1530.
43. Muralidharan G., Hawes E.M., McKay G., Midha K.K. Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Xenobiotica. 21:1991;1441-1450.
44. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci. Res. 29:1997;99-111.
45. Nagatsu T., Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci. Lett. 87:1988;178-182.
46. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
47. Niwa T., Tanaka N., Tatematsu A., Matsurra S., Yoshida M., Nagatsu T. Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. J. Chromatogr. 452:1988;85-91.
48. Niwa T., Yoshizumi H., Tatematsu A., Matsuura S., Nagatsu T. Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. J. Chromatogr. 493:1989;347-352.
49. Ohta S., Kohno M., Makino Y., Tachikawa O., Hirobe M. Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in the human brain: relation to Parkinson's disease. Biomed. Res. 8:1987;453-456.
50. Ohta S., Tachikawa O., Makino Y., Tasaki Y., Hirobe M. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci. 46:1990;599-605.
51. Pajeva I.K., Wiese M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J. Med. Chem. 45:2002;5671-5686.
52. Ram S., Saxena A.K., Jain P.C. 2-Substituted 4-hydroxy-1,2,3,4- tetrahydroisoquinolines. Indian J. Chem. 16B:1978;1019-1022.
53. Riedl A.G., Watts P.M., Jenner P., Marsden G.D. P450 enzymes and Parkinson's disease: the story so far. Mov. Disord. 13:1998;212-220.
54. Rommelspacher H., Susilo R. Tetrahydroisoquinolines and β-carbolines: putative natural substances in plants and mammals. Prog. Drug Res. 29:1985;415-459. (Birkhäuser Verlag basel. R.L.).
55. Schilter B., Omiecinski C.J. Regional distribution and expression modulation of cytochrome P-450 and epoxide hydrolase mRNA in the rat brain. Mol. Pharmacol. 44:1993;990-996.
56. Schulz-Utermoehl T., Bennett A.J., Ellis S.W., Tucker G.T., Boobis A.R., Edwards R.J. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics. 9:1999;357-366.
57. Shang T., Uihlein A.V., Van Asten J., Kalyanaraman B., Hillard C.J. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J. Neurochem. 85:2003;358-367.
58. Silverman J.A. Multidrug - resistance transporters. Pharm. Biotechnol. 12:1999;353-386.
59. Smith C.A.D., Gough A.C., Leigh P.N., Summers B.A., Harding A.E., Maranganore D.M., Sturman S.G., Schapira A.H.V., Williams A.C., Spurr N.K., Wolf C.R. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 1:1992;1375-1377.
60. Spector R. Drug transport in the central nervous system: role of carriers. Pharmacology. 40:1990;1-7.
61. Suzuki T., Fujita S., Narimatsu S., Masubuchi Y., Tachibana M., Ohta S., Hirobe M. Cytochrome P450 isoenzymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4,-tetrahydroisoquinoline in rat liver microsomes. FASEB J. 6:1992;771-776.
62. Tamai I., Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89:2000;1371-1388.
63. Tatsuta T., Naito M., Oh-hara T., Sugawara I., Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267:1992;20383-20391.
64. Tomas-Camardiel M., Sanchez-Hidalgo M.C., Sanchez Del Pino M.J., Navarro A., Machado A., Cano J. Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17 β-estradiol against 1-methyl-4- phenylpyridium toxicity on rat striatum. Neuroscience. 109:2002;569-584.
65. Tyndale R.F., Li Y., Li N.-Y., Messina E., Miksys S., Sellers E.M. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab. Dispos. 27:1999;924-930.
66. Weissman J., Trevor A., Chiba K., Peterson L.A., Caldera P., Castagnoli J.N. Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 28:1985;997-1001.
67. 2) and evidence for the expression of the transporter in the brain. J. Biol. Chem. 273:1998;32776-32786.
68. Yamakawa T., Kotake Y., Fujitani M., Shintani H., Makino Y., Ohta S. Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci. Lett. 276:1999;68-70.
69. Yoshida M., Niwa T., Nagatsu T. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. Neurosci. Lett. 119:1990;109-113.